On April 29, 2022, CMS released its Medicare Advantage and Part D final rule: Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs [CMS-4192-F].
Medicare-Medicaid integration is critically important for the millions of dual eligible individuals served by both programs. This Final Rule takes important steps in improving integration.
ATI Advisory prepared the below overview to provide stakeholders with a summary and insights into the key provisions impacting dual eligible beneficiaries. We also included key commentary and insights from the Rule that indicate potential future rulemaking and market impacts.
For examples of other public-facing ATI work related to dual eligible individuals, see below. For more information about how ATI can help you navigate research, policy, operational, or strategic issues related to dual eligible individuals, please contact us at info@atiadvisory.com.